American Cancer Society

Roche’s lung cancer combo treatment wins FDA approval

Accelerated Review, American Cancer Society, Approvals, Bladder Cancer, Blockbusters, Clinical Studies, Extensive-Stage Small Cell Lung Cancer, FDA, FDA/Regulatory, Immunotherapies, Lung Cancer, Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC), Urinary Tract Cancer

Roche Holding AG’s Tecentriq immunotherapy in combination with Avastin and chemotherapy won U.S. Food and Drug Administration approval as a first-line treatment for a type of lung cancer.

December 6, 2018/by Reuters Health

Molecular Templates, Takeda Strike MM Deal

American Cancer Society, Business, Cancer Cells, CD38 Proteins, Collaborations, Deals, Engineered Toxin Bodies (ETBs), Immune System, Immunotoxins, Multiple Myeloma, Multiple Myeloma Cells, Shares

Shares of Molecular Templates were up more than 52 percent after announcing a deal with Takeda that could be worth up to $632 million to develop CD38-targeted engineered toxin bodies.

September 20, 2018/by BioSpace

Array BioPharma gets FDA nod for melanoma combo treatment

American Cancer Society, Analysts, Approvals, BRAF-Mutant Melanoma, FDA, FDA/Regulatory, Genetics, Mutations, Shares, Skin Cancer

The U.S. Food and Drug Administration approved Array BioPharma Inc.’s oral combination treatment for use in patients with the deadliest form of skin cancer.

June 27, 2018/by Reuters Health

FDA approves Gilead cancer gene therapy

American Cancer Society, Analysts, Approvals, CAR-T Therapy, Costs, Diffuse Large B-Cell Lymphoma (DLBCL), FDA, FDA/Regulatory, Gene Therapy, Immune Cells, Large B-Cell Lymphoma, M&A, Non-Hodgkin Lymphoma, Pricing, Shares, T-Cells

U.S. regulators approved a new therapy for a type of lymphoma, which was developed by Gilead Sciences Inc.’s Kite Pharma.

October 18, 2017/by Reuters Health